Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro

This publication has 31 references indexed in Scilit:

• Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim
  Bone Marrow Transplantation, 2001
• Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma
  Cancer, 2000
• Role of SR-4987 stromal cells in the modulation of Doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (CFU-GM)
  Life Sciences, 1999
• Growth Factors and Cytokines Upregulate Gelatinase Expression in Bone Marrow CD34+ Cells and Their Transmigration Through Reconstituted Basement Membrane
  Blood, 1999
• Mobilization of Peripheral Blood Progenitor Cells by Betafectin® PGG‐Glucan Alone and in Combination with Granulocyte Colony‐Stimulating Factor
  The International Journal of Cell Cloning, 1998
• The Tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (Goralatide) Protects From Doxorubicin-Induced Toxicity: Improvement in Mice Survival and Protection of Bone Marrow Stem Cells and Progenitors
  Blood, 1998
• Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy.
  Supportive Care in Cancer, 1997
• Intensive Chemotherapy plus Recombinant Human Granulocyte Colony Stimulating Factor Support for Distant Metastatic Nasopharyngeal Carcinoma
  Oncology, 1997
• Increased bone marrow toxicity of doxorubicin bound to nanoparticles
  European Journal Of Cancer, 1994
• Enhancement of hematopoietic response of mice by intraperitoneal administration of a .BETA.-glucan, SSG, obtained from Sclerotinia sclerotiorum.
  Journal of Pharmacobio-Dynamics, 1990